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Background: Schizophrenia-like disorders can be divided into endogenic or primary, 
idiopathic, polygenetic forms, and different secondary, organic subgroups [e.g., 
(para)epileptic, immunological, degenerative]. Epileptic and paraepileptic explanatory 
approaches have a long tradition due to the high rate of electroencephalography (EEG) 
alterations in patients with schizophrenia.
Case presentation: We present the case of a 23-year-old female patient suffering, 
since the age of 14 years, from a fluctuating paranoid-hallucinatory syndrome with formal 
thought disorder, fear, delusions of persecution, auditory, visual, and tactile hallucina-
tions, as well as negative and cognitive symptoms. Laboratory measurements showed 
increased titers of antinuclear antibodies (ANAs) in the context of ulcerative colitis. While 
there was no clear history or evidence of epileptic seizures, the EEG showed generalized 
3 Hz polyspike wave complexes. Under treatment with levetiracetam, the symptoms 
disappeared and the patient was able to complete vocational training.
Conclusion: The schizophrenia-like symptoms associated with epileptiform discharges 
but not overt seizures and the good response to antiepileptic treatment could be inter-
preted in the context of a (para)epileptic pathomechanism. The EEG alterations might 
be due to a polygenetic effect due to different genes. Mild immunological mechanisms 
in the framework of ulcerative colitis and increased ANA titers might have supported the 
network instability. This case report illustrates (1) the importance of EEG screenings in 
schizophrenia, (2) a potential pathogenetic role of epileptiform discharges in a subgroup 
of patients with schizophrenia-like symptoms, and (3) that antiepileptic medication with 
levetiracetam could be a successful treatment alternative in schizophrenia-like disorders 
with EEG alterations.
Keywords: epilepsy, schizophrenia, epileptiform discharges, levetiracetam, paraepileptic, LaNI hypothesis
Abbreviations: ACR, American College of Rheumatology; ANA, antinuclear antibody; CSF, cerebrospinal fluid; EEG, elec-
troencephalography; FIRDA, frontal intermittent rhythmic delta activity; GABA, γ-aminobutyric acid; HV, hyperventilation; 
ICA, independent component analyses; IRDA; intermittent rhythmic delta activity; LANI, local area network inhibition; SLE, 
systemic lupus erythematosus; SV2A, synaptic vesicle glycoprotein 2A.
taBLe 1 | Diagnostic findings.
Serum basic diagnostics and blood count •	 Normal renal, liver, and thyroid values;
•	 Slightly increased C3d concentration (11.1 mg/l; reference value <9 mg/l);
•	 Normal blood count.
Serum autoantibody analyses •	 Normal thyroid autoantibodies (against thyroglobulin, thyroid peroxidase, and thyroid-stimulating hormone);
•	 Rheumatological screening: increased antinuclear antibodies (titer: 1:400; reference value <1:50) without clear 
extractable nuclear antigens; the anti-nucleosome antibodies were weakly positive;
•	 No antibodies against intracellular onconeural antigens (Yo, Hu, CV2/CRMP5, Ri, Ma1/2, SOX1), or the 
intracellular synaptic antigens (GAD, amphiphysin).
Cerebrospinal fluid (CSF) analyses •	 Normal white cell count, no blood–brain barrier dysfunction (normal protein concentration and albumin 
quotient);
•	 No CSF-specific oligoclonal bands, but a weak identical band in the CSF and serum;
•	 Antibodies against neuronal cell surface antigens [NMDAR, AMPA-R, GABA-B-R, VGKC complex  
(LGI1, Caspr2)] were negative.
Cerebral magnetic resonance imaging (1.5 T) •	 Normal brain findings;
•	 Additional examination findings included a benign lesion of the right frontoparietal skull without contrast 
enhancement (most likely equivalent with dermoid cysts; the criteria for monoclonal gammopathy of 
undetermined significance or multiple myeloma were not fulfilled).
Electroencephalography (during the first admission 
to our clinic in 2013, under the treatment with 
clozapine, aripiprazole, and citalopram)
•	 Frontal accentuated intermittent rhythmic delta activity (FIRDA) and generalized 3 Hz polyspike wave 
complexes.
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BaCKGRoUND
Schizophrenia-like disorders are characterized by delusional 
perception and delusions of control, hallucinations (e.g., com-
menting or discussing voices), thought insertion or withdrawal, 
cognitive impairment, thought disorders, or social withdrawal.1 
In addition to primary, endogenic or idiopathic, polygenetic 
forms, different secondary pathophysiological mechanisms [e.g., 
(para)epileptic, immunological, degenerative] can be assumed. 
Because of the high rates of electroencephalography (EEG) altera-
tions, ranging from 7 to 60% in patients with schizophreniform 
syndromes, epileptic and paraepileptic explanatory approaches 
have a long tradition (1–3). In line with this assumption, we 
reported the first case of a young patient with a schizophrenia-
like disorder, generalized spike-and-slow-wave complexes 
without epileptic seizures but with remission under treatment 
with valproate (4, 5). Immunological reasons might be due to 
autoantibody-associated autoimmune encephalitis, cerebral vas-
culitis, or collagenosis [e.g., systemic lupus erythematosus (SLE)] 
(6). Immunological effects might lead to network instability and 
therefore cause (para)epileptic phenomena (7). The detection of 
a (para)epileptic or immunological mechanism opens new treat-
ment perspectives, in that antiepileptics or immunomodulators 
may be helpful (4, 5, 7–10).
Case pReseNtatIoN
Clinical presentation
We present the case of a 23-year-old female office clerk suffering 
from fluctuating paranoid-hallucinatory symptoms since the age 
1 http://apps.who.int/classifications/icd10/browse/2010/en#/F20-F29.
of 14 years (2007). Therefore, the diagnosis of paranoid schizo-
phrenia was made by different psychiatrists. Although taking 
neuroleptics, in the course of the disease, the patient developed 
five episodes (for several weeks) with paranoid-hallucinatory 
exacerbation. In these episodes, the patient suffered from formal 
thought disorder, fear, delusions of persecution, auditory halluci-
nations with commenting, discussing, and commanding voices, 
visual hallucinations with seeing maggots in her room, and tactile 
hallucinations with the feeling of being touched from behind. In 
parallel to these exacerbations, the patient developed severe nega-
tive and cognitive symptoms including attention and memory 
deficits, fatigue, depressive mood, and sleep disturbances thus 
completing the psychopathological features of comprehensive 
schizophrenia. Neurological and medical examinations were 
normal.
Family History
There was a positive family history for unipolar depression, 
which was diagnosed earlier in two sisters, both parents, and 
both grandmothers. There was no history for schizophrenia-like 
psychopathology, bipolar disorder, or epilepsy.
somatic and Developmental History
Symptoms started 6 weeks after pain of the large joints. Therefore, 
a rheumatological disease was discussed. During an external 
work-up of repeated diarrhea, a chronic inflammation gut dis-
ease (ulcerative colitis) was diagnosed in 2014 and treated with 
mesalazine. No birth complications or in  utero abnormalities 
were remembered; the birth was performed by cesarean sec-
tion. The early childhood development was normal. No febrile 
convulsions or inflammatory brain diseases were remembered. 
The patient suffered mild cerebral contusions at the age of 4 and 
12 years.
FIGURe 1 | Frontal accentuated intermittent rhythmic delta activity (FIRDa, left) and generalized 3 Hz polyspike wave complexes (middle) in the 
bipolar longitudinal rows (7 µV/mm, 0.3 s, 70 Hz). the findings of the independent component analysis are presented in the right picture [the following 
four relevant components were found, left: activity traces, with examples of atypical activity cut from the clinical electroencephalography and appended at the dotted 
lines. Right: topographies, nose upward, negative (direction opposite of activity trace) blue, positive (direction same as activity trace) red. Right (component 3) and 
left (component 5) frontal activity show most prominent ~2.6 Hz bursts. Higher frequency activity frontocentral (component 2) and occipital (alpha component 7) are 
partially related].
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Diagnostic Findings
The diagnostic findings are summarized in Table  1. Taken 
together, the immunological alterations were compatible with the 
previously known ulcerative colitis (11). The electrophysiological 
findings (Figure  1) would be compatible with primary (idi-
opathic) generalized epilepsy; however, the history for epileptic 
seizures including absences and myoclonic jerks was negative.
Differential Diagnosis
The schizophreniform symptoms fulfilled the criteria of paranoid-
hallucinatory schizophrenia (see footnote 1). Therefore, the most 
important differential diagnoses would be schizophrenia plus 
coincidental epileptiform discharges. Although the findings of 
the investigation led us to our consideration of neuropsychiatric 
SLE, the American College of Rheumatology classification crite-
ria for SLE were not fulfilled.2
therapy and outcome
External neuroleptic treatment with risperidone (4  mg), ami-
sulpride (600  mg), perazine (100  mg), aripiprazole (15  mg), 
and clozapine (275 mg) did not lead to long-term stabilization. 
Additional treatment with fluoxetine (20  mg) and citalopram 
(20 mg) for affective, negative, and cognitive symptoms did not 
successfully improve these symptoms. During the first visit in 
our clinic, in 2013, we detected the abovementioned epileptiform 
discharges. Assuming a (para)epileptic pathomechanism, we 
added antiepileptic treatment with valproate (1,500 mg) to the 
neuroleptic medication with clozapine and aripiprazole. At this 
point, the cognitive deficits improved significantly. Also, the EEG 
improved except for the (F)IRDAs. Another paranoid-hallucina-
tory episode in 2014 was treated successfully with a dose increase 
of clozapine and valproate. Because of a strong weight gain, the 
therapy with valproate was changed to topiramate (200 mg) in 
2014. Assuming a (para)epileptic pathomechanism, clozapine 
was reduced and stopped in 2014. Aripiprazole was reduced in 
2 www.rheumatology.org/Portals/0/Files/1997%20Update%20of%201982%20
Revised.pdf.
January 2014 and stopped in 2015. Normal results were found 
in both the routine EEG and in the EEG after sleep deprivation 
(2014). In the further course, topiramate led to a severe loss of 
appetite and was therefore changed to levetiracetam (1,500 mg) 
in 2014. The mental condition stabilized with the short-term 
antiepileptic treatment with topiramate and the subsequent antie-
pileptic treatment with levetiracetam (since 2014, and since 2015 
as monotherapy). There were no more paranoid-hallucinatory 
episodes, the negative symptoms declined, the patient became a 
mother (in the spring of 2016); she lived alone, took care of her 
daughter, and simultaneously finished her vocational training (in 
the summer of 2016). She was able to suspend the mesalazine 
therapy and therefore only took levetiracetam (1,500 mg) at the 
time of stabilization.
DIsCUssIoN
We present the case of a patient with a schizophrenia-like disorder 
and, following our judgment, a (para)epileptic pathomechanism, 
because of the distinct epileptiform discharges without seizures 
and remission under the anticonvulsive treatment with topira-
mate and subsequently levetiracetam monotherapy.
Reason and potential pathophysiology  
of Network Instability
The EEG alterations might be due to a polygenetic effect caused 
by different genes (12). The immunological mechanisms in 
the framework of ulcerative colitis and increased antinuclear 
antibody titers might have supported the network instability by 
mild inflammatory processes (7, 13–15). Medication might also 
disclose underlying polygenetic or immunological network insta-
bility (16). The local area network inhibition (LANI) hypothesis 
might explain the causal relationship between epileptiform EEG 
discharges and schizophrenia-like symptoms. Excitatory network 
activity, as represented by the 3 Hz polyspike wave complexes, 
might lead to consecutive inhibitory processes in a physiological 
attempt of the central nervous system to stabilize the excitatory–
inhibitory equilibrium of local cerebral networks. The repetitive 
4Endres et al. Paraepileptic Schizophrenia
Frontiers in Psychiatry | www.frontiersin.org February 2017 | Volume 8 | Article 12
excitatory activity, as documented by consecutive EEGs in our 
patient, could have exceeded a critical threshold, leading to the 
successive hyperinhibition of cerebral networks. Following the 
LANI hypothesis, the symptoms are due to the secondary induced 
processes of hyperinhibition (e.g., temporal hyperinhibition 
might have led to auditory hallucinations or memory deficits) 
(2–5, 17).
treatment Considerations
Following the LANI hypothesis, the cognitive improvement 
after the addition of valproate to the neuroleptic treatment 
would be explained by the reduced epileptic activity and 
therefore the subsequent amelioration of inhibitory processes. 
In line with this assumption, comprehensive long-term stabi-
lization was not achieved by several attempts of neuroleptic 
medication alone in spite of clear and very convincing effects 
of the treatment with clozapine in particular on positive 
symptoms. However, such a comprehensive improvement and 
even full remission was achieved with topiramate and later 
levetiracetam monotherapy. Thus, clozapine with its well-
known proconvulsive properties might well have counteracted 
inhibitory processes, while it is at the same time most likely 
unable to improve causative excitatory neuronal activity. By 
contrast, by reducing the epileptiform activity, topiramate 
and levitiracetam monotherapy might have resulted in a more 
causal and therefore more comprehensive improvement of rel-
evant pathophysiology. Earlier, we published a case of a (para)
epileptic schizophrenia-like disorder successfully treated with 
valproate (4). Valproate, and likewise lamotrigine, is already 
established as an augmentative treatment strategy in schizo-
phrenia (18). One might hypothesize that patients with (para)
epileptic pathomechanisms will benefit significantly more 
from antiepileptic treatment than other subgroups. To our 
knowledge, this is the first published case study that describes 
a patient with a schizophrenia-like disorder who was success-
fully treated with levetiracetam. Levetiracetam is rarely used 
off-label in psychiatry probably because of its potential side 
effects, such as agitation, aggression, fear, and psychosis (2). 
The advantage of levetiracetam is that it can be rapidly dosed 
up to effective concentrations. Therefore, on a single case basis, 
the working hypothesis of a (para)epileptic pathomechanism 
could be tested quickly. In comparison, valproate effects could 
be due to combined γ-aminobutyric acid (GABAergic) and 
antiglutamatergic effects, and lamotrigine effects might be due 
to potential antiglutamatergic effects. However, the mechanism 
of levetiracetam cannot be explained by such direct transmitter 
effects. The effects of levetiracetam seem to be associated with 
the binding of the synaptic vesicle glycoprotein 2A (SV2A) (2). 
SV2A can be found in presynaptic membranes; it controls the 
calcium-dependent exocytosis of different neurotransmitters 
into the synaptic gap (19, 20). Therefore, it might also influence 
GABAergic and glutamatergic transmission (21).
Limitations
Epileptiform discharges are found in less than 1% of healthy 
adults (1, 22–24) and as a rare consequence of clozapine treat-
ment (16). Therefore, the EEG alterations could be interpreted 
either as an incidental finding in a patient with schizophrenia 
or as a clozapine side effect. However, the clinical course—with 
improvement under antiepileptic treatment in parallel with EEG 
normalization—speaks against the assumption. The pathophysi-
ological processes might be explained by the LANI hypothesis; 
however, this is only an unproven, theoretical framework that 
needs further investigation.
Conclusion
This case report illustrates the idea of a possible (para)epileptic 
pathomechanism in a patient with a schizophrenia-like disorder. 
Regarding diagnostic procedure, our case shows the importance 
of EEG examinations in typical schizophrenia-like disorders. 
Regarding pathophysiology, the case illustrates a potential 
pathogenetic role of epileptiform discharges in a subgroup of 
patients with schizophrenia-like symptoms. Regarding treat-
ment, the case demonstrates that anticonvulsive medication 
with levetiracetam and also topiramate or valproate could be 
a successful treatment alternative in schizophrenia with EEG 
alterations.
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